ARB-1740 / Arbutus - LARVOL DELTA

ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. (PubMed, ACS Infect Dis) - "Combination of ARB-1740 with a capsid inhibitor and pegylated interferon-alpha led to greater liver HBsAg reduction which correlated with more robust induction of innate immune responses in a human chimeric mouse model of HBV. The preclinical profile of ARB-1740 demonstrates the promise of RNA interference and HBV antigen reduction in treatment strategies driving towards a cure for HBV."

Journal

Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model. (PubMed, ACS Infect Dis) - "In contrast, HDV-targeting siRNA inhibited HDV in both blood and liver compartments without affecting HBV and pegylated interferon-alpha reduced HBV viremia by 2.0 log but had no effect on HDV viremia under these study conditions. These results illustrate the inhibitory effects of siRNAs against these two viral infections and suggest that ARB-1740 may be of therapeutic benefit for hepatitis delta patients, a subpopulation with high unmet medical need."

Journal • Preclinical

Research progress of siRNA in reducing serum HBsAg levels in patients with chronic hepatitis B (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "Clinical studies have identified JNJ-3989 (ARO-HBV) and ARB-1740 as well-tolerated siRNA drugs, which significantly reduce HBsAg levels. This article expounds the main mechanisms of siRNA in inhibiting HBsAg expression, improving target and stability as well as relevant preclinical and clinical studies."

Clinical • Journal • Review